From in vivo to in vitro : The medical device testing paradigm shift

Lade...
Vorschaubild
Dateien
Kerecman Myers_2--1lvvo1jz1o7nv9.pdf
Kerecman Myers_2--1lvvo1jz1o7nv9.pdfGröße: 1.63 MBDownloads: 404
Datum
2017
Autor:innen
Kerecman Myers, Dayna
Goldberg, Alan M.
Poth, Albrecht
Wolf, Michael F.
Carraway, Joseph
McKim, James M.
Coleman, Kelly P
Hutchinson, Richard
Brown, Ronald
Krug, Harald F
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Open Access Gold
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Alternatives to Animal Experimentation : ALTEX. 2017, 34(4), pp. 479-500. ISSN 0946-7785. eISSN 1868-8551. Available under: doi: 10.14573/altex.1608081
Zusammenfassung

Amid growing efforts to advance the replacement, reduction, and refinement of the use of animals in research, there is a growing recognition that in vitro testing of medical devices can be more effective, both in terms of cost and time, and also more reliable than in vivo testing. Although the technological landscape has evolved rapidly in support of these concepts, regulatory acceptance of alternative testing methods has not kept pace. Despite the acceptance by regulators of some in vitro tests (cytotoxicity, gene toxicity, and some hemocompatibility assays), many toxicity tests still rely on animals (irritation, sensitization, acute toxicity, reproductive/developmental toxicity), even where other industrial sectors have already abandoned them. Bringing about change will require a paradigm shift in current approaches to testing - and a concerted effort to generate better data on risks to human health from exposure to leachable chemicals from medical devices, and to boost confidence in the use of alternative methods to test devices. To help advance these ideas, stir debate about best practices, and coalesce around a roadmap forward, the JHU-Center for Alternatives to Animal Testing (CAAT) hosted a symposium believed to be the first gathering dedicated to the topic of in vitro testing of medical devices. Industry representatives, academics, and regulators in attendance presented evidence to support the unique strengths and challenges associated with the approaches currently in use as well as new methods under development, and drew next steps to push the field forward from their presentations and discussion.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
in vitro testing, refinement, skin sensitization, threshold of toxicological concern (TTC), nanotoxicology
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690KERECMAN MYERS, Dayna, Alan M. GOLDBERG, Albrecht POTH, Michael F. WOLF, Joseph CARRAWAY, James M. MCKIM, Kelly P COLEMAN, Richard HUTCHINSON, Ronald BROWN, Harald F KRUG, Anthony BAHINSKI, Thomas HARTUNG, 2017. From in vivo to in vitro : The medical device testing paradigm shift. In: Alternatives to Animal Experimentation : ALTEX. 2017, 34(4), pp. 479-500. ISSN 0946-7785. eISSN 1868-8551. Available under: doi: 10.14573/altex.1608081
BibTex
@article{KerecmanMyers2017vitro-40825,
  year={2017},
  doi={10.14573/altex.1608081},
  title={From in vivo to in vitro : The medical device testing paradigm shift},
  number={4},
  volume={34},
  issn={0946-7785},
  journal={Alternatives to Animal Experimentation : ALTEX},
  pages={479--500},
  author={Kerecman Myers, Dayna and Goldberg, Alan M. and Poth, Albrecht and Wolf, Michael F. and Carraway, Joseph and McKim, James M. and Coleman, Kelly P and Hutchinson, Richard and Brown, Ronald and Krug, Harald F and Bahinski, Anthony and Hartung, Thomas}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/40825">
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-12-04T13:08:53Z</dc:date>
    <dc:creator>Carraway, Joseph</dc:creator>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:title>From in vivo to in vitro : The medical device testing paradigm shift</dcterms:title>
    <dc:contributor>Poth, Albrecht</dc:contributor>
    <dc:creator>Krug, Harald F</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/40825"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Bahinski, Anthony</dc:creator>
    <dc:contributor>Wolf, Michael F.</dc:contributor>
    <dc:contributor>Krug, Harald F</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-12-04T13:08:53Z</dcterms:available>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dc:creator>Hutchinson, Richard</dc:creator>
    <dc:contributor>Kerecman Myers, Dayna</dc:contributor>
    <dc:creator>McKim, James M.</dc:creator>
    <dc:creator>Coleman, Kelly P</dc:creator>
    <dc:language>eng</dc:language>
    <dc:contributor>Hutchinson, Richard</dc:contributor>
    <dc:contributor>Brown, Ronald</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>McKim, James M.</dc:contributor>
    <dc:creator>Brown, Ronald</dc:creator>
    <dcterms:issued>2017</dcterms:issued>
    <dc:creator>Poth, Albrecht</dc:creator>
    <dc:creator>Kerecman Myers, Dayna</dc:creator>
    <dcterms:abstract xml:lang="eng">Amid growing efforts to advance the replacement, reduction, and refinement of the use of animals in research, there is a growing recognition that in vitro testing of medical devices can be more effective, both in terms of cost and time, and also more reliable than in vivo testing. Although the technological landscape has evolved rapidly in support of these concepts, regulatory acceptance of alternative testing methods has not kept pace. Despite the acceptance by regulators of some in vitro tests (cytotoxicity, gene toxicity, and some hemocompatibility assays), many toxicity tests still rely on animals (irritation, sensitization, acute toxicity, reproductive/developmental toxicity), even where other industrial sectors have already abandoned them. Bringing about change will require a paradigm shift in current approaches to testing - and a concerted effort to generate better data on risks to human health from exposure to leachable chemicals from medical devices, and to boost confidence in the use of alternative methods to test devices. To help advance these ideas, stir debate about best practices, and coalesce around a roadmap forward, the JHU-Center for Alternatives to Animal Testing (CAAT) hosted a symposium believed to be the first gathering dedicated to the topic of in vitro testing of medical devices. Industry representatives, academics, and regulators in attendance presented evidence to support the unique strengths and challenges associated with the approaches currently in use as well as new methods under development, and drew next steps to push the field forward from their presentations and discussion.</dcterms:abstract>
    <dc:contributor>Coleman, Kelly P</dc:contributor>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/40825/1/Kerecman%20Myers_2--1lvvo1jz1o7nv9.pdf"/>
    <dc:contributor>Carraway, Joseph</dc:contributor>
    <dc:creator>Goldberg, Alan M.</dc:creator>
    <dc:creator>Wolf, Michael F.</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/40825/1/Kerecman%20Myers_2--1lvvo1jz1o7nv9.pdf"/>
    <dc:contributor>Goldberg, Alan M.</dc:contributor>
    <dc:contributor>Bahinski, Anthony</dc:contributor>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Diese Publikation teilen